Men’s Health spoke to Novo Nordisk's Thomas Kruse and Jesper Lau, the two chemists responsible for discovering semaglutide—the main ingredient in Ozempic and Wegovy.

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber device.

On April 14, Novo Nordisk announced that it had entered into a partnership with OpenAI. The two companies will collaborate to bring cutting-edge artificial intelligence (AI) capabilities to the drug ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Novo Nordisk once benefited from euphoric sentiment around the booming GLP-1 market. Rising competition and decelerating growth has inspired investors to rotate capital elsewhere. The company's ...

With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled positive results that could tee up an expansion in semaglutide’s inaugural ...